RxDoctor Payments Data

Robert Malkin, MD

Cardiovascular Disease · New Britain, CTNPI 1689630766

Payments from drug & device makers

$16,290in general payments, 2019–2025

Across 918 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Pfizer$1K
  • Novartis$1K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Alnylam Pharmaceuticals Inc.$911
  • plus $8K from 35 others

What the payments were for

  • Food & beverage$16,215100%
  • Education$740%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,290 in reported general payments places this provider in the 85th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$399,512
Medicare patients
1,097
Services billed
3,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban666$712,199
XareltoRivaroxaban354$471,189
EntrestoSacubitril/Valsartan120$204,507
MultaqDronedarone Hcl40$70,505
BrilintaTicagrelor57$63,831
JardianceEmpagliflozin30$51,067
Repatha SureclickEvolocumab37$35,963
CorlanorIvabradine Hcl16$20,867
FarxigaDapagliflozin Propanediol15$20,826
LivaloPitavastatin Calcium13$10,589
Repatha SyringeEvolocumab17$8,494
Ranolazine ErRanolazine63$8,368
Metoprolol Succinate621$7,493
Torsemide370$7,445
PradaxaDabigatran Etexilate Mesylate17$5,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,396$712,199666 claims
Johnson & JohnsonXarelto$1,947$471,189354 claims
NovartisEntresto$1,333$204,507120 claims
AstraZenecaBrilinta, Farxiga$703$84,65872 claims
Sanofi-aventis U.S. LLCMultaq$306$70,50540 claims
Boehringer IngelheimJardiance, Pradaxa$1,238$56,65147 claims
AmgenCorlanor$1,248$20,86716 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$252$16,16227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →